Carbopa-50/Carbopa-150/Carbopa-450

Carbopa-50/Carbopa-150/Carbopa-450

carboplatin

Manufacturer:

Accord Healthcare

Distributor:

DKSH
Concise Prescribing Info
Contents
Carboplatin
Indications/Uses
Treatment of advanced stage ovarian cancer of epithelial origin.
Dosage/Direction for Use
Previously untreated adult (w/ normal renal function) 400 mg/m2 by IV infusion over 15 min to 1 hr. Doses should not be given more frequently than every 4 wk. Renal failure CrCl 41-56 mL/min Initially 250 mg/m2. CrCl 16-40 mL/min Initially 200 mg/m2.
Contraindications
Hypersensitivity to carboplatin or other platinum containing compd. Severe myelosuppression; bleeding tumours; pre-existing severe renal impairment (CrCl ≤20 mL/min). Breast-feeding.
Special Precautions
Patients w/ abnormal kidney function or receiving concomitant therapy w/ other drugs w/ nephrotoxic potential. Assess carefully renal function parameters before & during therapy. Infusion courses should not be repeated more frequently than mthly under normal circumstances. Monitor peripheral blood counts frequently. Combination therapy w/ other myelosuppressive compds. Supportive transfusional therapy may be required in patients who suffer severe myelosuppression. May cause nausea & vomiting. Renal & hepatic function impairment. Increased incidence of allergic reactions w/ previous exposure to platinum therapy. Perform neurological evaluation & assessment of hearing on a regular basis especially when receiving high dose. Do not use Al containing equipment during prep & administration. Women of childbearing potential & pregnancy. Childn.
Adverse Reactions
Bone marrow suppression, anaemia; vomiting, nausea; peripheral neuropathies; reduced CrCl, elevated serum creatinine, BUN & uric acid levels; abnormal liver function tests (eg, SGOT, total bilirubin & alkaline phosphatase); hypocalcaemia, hypomagnesaemia, hypokalemia, hyponatremia, increased BUN, increased uric acid; hypersensitivity; ototoxicity (tinnitus & hearing loss); pain & asthenia.
Drug Interactions
Increased risk of induced nephrotoxicity & ototoxicity w/ aminoglycosides (eg, amikacin, gentamycin, tobramycin). May decrease serum level of phenytoin. May decrease serum level of phenytoin. May increase anticoagulant effect of warfarin. May potentiate renal effects of nephrotoxic drugs. May cause more severe bone marrow depression w/ bone marrow suppressing drugs or w/ radiotherapy.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01XA02 - carboplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.
Presentation/Packing
Form
Carbopa-450 soln for infusion 450 mg/45 mL
Packing/Price
1's
Form
Carbopa-50 soln for infusion 50 mg/5 mL
Packing/Price
1's
Form
Carbopa-150 soln for infusion 150 mg/15 mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in